Prostate Cancer Clinical Trials in Minneapolis

Showing 201-220 of 276 trials

Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.

NCT02445976

The goal of this clinical study is to determine the efficacy and safety of Seviteronel, a lyase-selective inhibitor of CYP17 and an androgen receptor antagonist, in patients with castration-resistant prostate cancer (CRPC) who have been previously treated with enzalutamide and/or abiraterone.

Prostate Cancer

Innocrin Pharmaceutical197 participantsStarted May 2015

Birmingham, Alabama, United States • Scottsdale, Arizona, United States • Los Angeles, California, United States +18 more locations

COMPLETEDPhase 2< 1 mile

Vidaza to Restore Hormone Thx Prostate

NCT00384839

The purpose of this research study is to find out what effects (good and bad) Vidaza has on patients with prostate cancer. This investigational drug is not approved by the Food and Drug Administration (FDA) for the treatment of prostate cancer; however, it is approved in myelodysplastic syndrome - a bone marrow disease. The pharmaceutical company involved in this study, Pharmion Corporation, is the manufacturer of Vidaza.

Prostate Cancer

US Oncology Research36 participantsStarted Apr 2006

Denver, Colorado, United States • Ocoee, Florida, United States • Minneapolis, Minnesota, United States +10 more locations

Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.

Vidaza to Restore Hormone Thx Prostate

Prostate Cancer Trials in Other Cities

Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors

Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

Tadalafil in Preventing Erectile Dysfunction in Patients With Prostate Cancer Treated With Radiation Therapy

Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer

Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss

A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer

Collection of Patient-Reported Symptoms and Performance Status Via the Internet

A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer

Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer

Bone Health Observational Study

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer

Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer

Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer

Other Conditions in Minneapolis